Trial Profile
An Ascending Multiple Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MYO-029 Administered Intravenously as a 30-Minute Infusion to Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Stamulumab (Primary)
- Indications Muscular dystrophies
- Focus Adverse reactions
- Sponsors Pfizer
- 30 May 2014 New trial record